Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bayer AG : EARNINGS FORECAST TABLE : Bayer 4Q 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 02:32pm CEST

FRANKFURT--The following is a summary of analysts' forecasts for Bayer AG (BAYN.XE) fourth-quarter results, based on a poll of 10 analysts conducted by Dow Jones Newswires (figures in million euros, EPS, dividend and target price in euro, according to IFRS). Earnings figures are scheduled to be released February 28.

=== 
 
                          EBITDA   EBITDA   EBIT    EBIT 
4th Quarter        Sales    adj.    rep.    adj.  reported 
 
AVERAGE            9,726   1,811   1,585   1,092     901 
Prev. Year         9,191   1,541   1,415     844     629 
+/- in %            +5.8     +18     +12     +29     +43 
 
MEDIAN             9,743   1,821   1,585   1,102     841 
Maximum            9,905   1,893   1,633   1,191   1,053 
Minimum            9,536   1,707   1,536     970     808 
Amount (a)            10      10       2       6       5 
 
Baader Bank        9,725   1,839      --      --      -- 
Credit Suisse      9,793   1,831      --   1,191     966 
Deutsche Bank      9,559   1,869      --   1,135   1,053 
Equinet            9,760   1,820      --      --     838 
Exane BNP Paribas  9,611   1,817      --     970      -- 
J.P. Morgan        9,883   1,821   1,633   1,125      -- 
Nomura             9,536   1,707      --   1,078     808 
UBS                9,840   1,760      --      --      -- 
 
 
 
                  Net attrib.             EPS 
4th Quarter         income      EPS      core 
 
AVERAGE              468       0.55      1.06 
Prev. Year           397       0.48      0.97 
+/- in %             +18        +15      +9.3 
 
MEDIAN               494       0.53      1.06 
Maximum              549       0.66      1.12 
Minimum              332       0.46      1.00 
Amount (a)             8          6        10 
 
Baader Bank          542         --      1.02 
Credit Suisse        466       0.56      1.05 
Deutsche Bank        538         --      1.05 
Equinet               --       0.50      1.08 
Exane BNP Paribas    332         --      1.09 
J.P. Morgan          521       0.63      1.06 
Nomura               413       0.50      1.00 
UBS                   --         --      1.03 
 
 
 
               Target price  Rating                 DPS 2012 
 
AVERAGE               77.27  positive 6     AVERAGE     1.84 
Prev. Quarter         67.20  neutral  3     Prev. Year  1.65 
+/- in %                +15  negative 1     +/- in %     +11 
 
MEDIAN                75.00                 MEDIAN      1.83 
Maximum               90.00                 Maximum     1.94 
Minimum               65.60                 Minimum     1.77 
Amount                    9                 Amount         6 
 
Baader Bank           65.60  Hold                         -- 
Barclays              66.00  Underweight                1.81 
Citigroup             90.00  Buy                        1.85 
Commerzbank           90.00  Buy                          -- 
Credit Suisse         82.80  Outperform                 1.94 
Deutsche Bank         86.00  Buy                        1.77 
Equinet               75.00  Accumulate                 1.85 
Exane BNP Paribas     73.00  Neutral                    1.80 
J.P. Morgan              --  Overweight                   -- 
UBS                   67.00  Neutral                      -- 
=== 

Year-earlier figures are as reported by the company.

(a) Including anonymous estimates from two more institutes.

DJG/voi 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
05/26 COVESTRO : names new CEO to replace Patrick Thomas
05/25 BAYER : Findings from Bayer Has Provided New Data on Non-Small Cell Lung Cancer ..
05/24 BAYER : Federal Contracts Awarded by Federal Agencies in Connecticut (May 24)
05/24 DGAP-ADHOC : Covestro AG: CEO succession planning
05/24 Freeze Drying Agenda Released for Lyophilization USA 2017
05/23 GLOBAL HERBICIDE RESISTANCE CHALLENG : Adrian Percy: ”We invest in finding..
05/23 BAYER : $165,000 Federal Contract Awarded to iMed Biomedical
05/20 COVESTRO : to expand CO2-using processes
05/19 BAYER : Combine Solicitation - MEDRAD Injector Maintenance
05/18 RESEARCHERS AT BAYER TARGET HEART DI : A Prodrug of a Partial Adenosine A Recept..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 Mergers And Acquisitions - Capturing The Gain (Of Acquirees)
05/21 Tracking Dan Loeb's Third Point Portfolio - Q1 2017 Update
05/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 18, 2017
05/18 Bayer on deck with nine abstracts at ASCO
05/17 FDA grants Priority Review for Bayer's NDA for copanlisib for follicular lymp..